|CFN99505||Aristolochic acid A
Aristolochic acid A is a potent nephrotoxin, which strongly induced toxic damage during ovarian maturation by inhibiting Akt phosphorylation-mediated suppression of apoptosis.
Colchicine is a tubulin inhibitor, and a microtubule polymerization inhibitor with an IC50 of 3 nM. It prevents amyloidosis in our high-risk population and that it can prevent additional deterioration of renal function in patients with amyloidosis who have proteinuria but not the nephrotic syndrome. Colchicine has anti-mitotic activity, it can be used to treat familial mediterranean fever, and as a lead compound for the generation of potent anti-cancer drugs.
Norcantharidin has been used to treat human cancers in China since 1984, it inhibits the canonical Wnt signal pathway in NSCLC, by activating WIF-1 via promoter demethylation; it also enhances TIMP‑2 antitumor and anti‑vasculogenic mimicry activities in GBCs through downregulating MMP‑2 and MT1‑MMP. Norcantharidin is a protein phosphatase type-2A inhibitor, which has less nephrotoxic and phlogogenic side-effects, it can inhibit both DNA synthesis and granulocyte-macrophage colony-forming cells (GM-CFC)growth and impaire the neogenesis of chromatin material and nuclear membrane during the M/G1 phase transition in K-562 cells.
1. Strictosamide may have important effects on inflammation and inflammatory pain.
2. Strictosamide is slightly toxic to Charles River mouse (LD(50)=723.17 mg/kg), producing CNS depression and kidney toxicity.
3. Strictosamide has nonsignificant in vitro and in vivo effect on kidney Na(+),K(+)-ATPase activity but produced an in vivo increase of Na(+),K(+)-ATPase activity of brain.
4. Strictosamide possesses antibacterial and antiviral activities.
Telocinobufagin is a novel endogenous digitalis, it shows a reversible local anesthetic action, similar to BUPI, however, without cardiac toxicity in vitro. Telocinobufagin has antimicrobial, potential immune system regulatory effects, it could be developed as a novel immunotherapeutic agent to treat and other immune-mediated diseases, and it may become a new immunomodulatory agent in many regions.